Abstract In this study, we attempted to develop a multimodality approach using chemotherapeutic agent mitomycin C, biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L), and mild hyperthermia to treat colon cancer. For this study, human colon cancer LS174T, LS180, HCT116 and CX-1 cells were infected with secretory
Introduction
Colorectal cancer is the third leading cause of cancer-related mortality in the world. The main cause of death of patients with colorectal cancer is metastases [1] . In the last decade, the medical control of metastatic colorectal cancer has shown remarkable advances. For example, the addition of oxaliplatin and irinotecan to previously existing 5-fluorouracil (5-FU) and leucovorin-based therapies improved the overall median survival of 12 months [2] , and with the addition of biological targeted therapies such as bevacizumab and cetuximab, the overall median survival rose to 20 months [3] [4] [5] [6] [7] [8] . However, systemic chemotherapeutic strategies are currently used only as palliatives-they do not improve long-term survival rates. Therefore, new approaches are necessary to improve the overall median survival for metastatic colorectal cancers such as hepatic colorectal metastases and colorectal peritoneal carcinomatosis. Current standard of care for hepatic colorectal metastases and colorectal peritoneal carcinomatosis is hyperthermic isolated hepatic perfusion (HIHP) therapy and hyperthermic intraperitoneal chemotherapy (HIPEC), respectively [9, 10] . These therapies are combinatorial treatments of chemotherapeutic agents and mild hyperthermia. We hypothesize that a multimodality [chemotherapeutic agent mitomycin C, biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/ Apo-2L), and mild hyperthermia] approach effectively enhances apoptotic death and improves the current standard of care to treat advanced colorectal metastases. To test the hypothesis, in this study, we focus on the effect of multimodality treatment on cell death in in vitro system.
Chemotherapy is the standard clinical treatment for human cancers. Chemotherapeutics can interact with DNA and activate several intracellular signal pathways including apoptosis [11] . Mitomycin C is an antibiotic which has been used as a chemotherapeutic agent in a variety of carcinogenic solid tumors including colon [12] , breast [13] , lung [14] and bladder [15] . Mitomycin C causes cross-links in the DNA molecules of the cells, leading to the formation of DNA interstrands and inhibiting DNA replication and transcription [16, 17] . Previous reports suggest that mitomycin C produces a consistent response when used as a single agent [18] [19] [20] [21] . However, like many other chemotherapeutic agents, mitomycin C may induce resistance to chemotherapy and may target normal cells, thus causing unexpected side effects at therapeutic doses. On the other hand, since mitomycin C offers a suitably low toxicity and can be easily delivered to an outpatient, it seems a reasonable, costeffective candidate for combinational therapy of colorectal cancer, like irinotecan [22] , capecitabine [23] or 5-FU [24] . TRAIL, a highly promising anticancer agent, is a cytokine of the TNF family which binds to the death receptors DR4 [25] [26] [27] and DR5 [28] [29] [30] . It has the unique ability to induce apoptosis in many transformed cancer cell lines, but not in normal tissue [31, 32] . Previous studies suggest that TRAILinduced apoptosis can be enhanced by combinational therapy with several chemotherapeutic agents at non-toxic doses in cancer cells [33] [34] [35] [36] [37] [38] . Nonetheless, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods, and TRAIL-resistant cancer cell populations [39] . To solve these limitations, we attempt to develop a secretory TRAIL-armed adenoviral vector.
Hyperthermia has been explored as an anticancer agent for many decades and is often used with HIPEC. We previously reported that hyperthermia has a synergistic effect with TRAIL in causing cytotoxicity through the mitochondria-dependent pathway [40] [41] [42] [43] . Several researchers also reported that hyperthermia acts synergistically with ionizing radiation [44] [45] [46] , and with a number of chemotherapeutic agents [47] [48] [49] . We previously reported that hyperthermia triggered down-regulation of c-FLIP L (long form of cellular FLICE-inhibitory protein), an anti-apoptotic molecule, in several colon cancer cells [50] . c-FLIP splice variants (long and short form) bind to FADD and/or caspase 8/10 and inhibit their activation [51] [52] [53] .
In this study, we observed that a combinatorial treatment of mitomycin C, adenoviral TRAIL and hyperthermia effectively activates the mitochondrial-dependent apoptotic pathway by activating the JNK-Bcl-xL-Bak pathway, increasing Bak oligomerization, facilitating cytochrome c release, promoting dissociation of Beclin-1 from Bcl-xL, and increasing Beclin-1 cleavage.
Materials and methods

Cell culture
The human colon adenocarcinoma line LS174T was kindly provided by Dr. HA Choudry (University of Pittsburgh Medical Center, Pittsburgh, PA, USA) and LS180 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The human colorectal carcinoma HCT116 wild type was obtained from Dr. B Vogelstein (Johns Hopkins University) and CX-1 cell line was obtained from Dr. JM Jessup (National Cancer Institute). Cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Gaithersburg, MD, USA), McCoy's 5A or RPMI 1640 supplemented with 10 % fetal bovine serum (FBS, Atlanta Biological, Flowery Branch, GA, USA), 100 U/mL penicillin and 100 lg/mL streptomycin (Gibco) in a 5 % CO 2 incubator. These adherent cells, except for LS180, were subcultured every 3-4 days by treatment with a trypsin-EDTA solution (Gibco). The LS180 cell line was cultured by following a procedure of ATCC subculturing.
Reagents and antibodies
Mitomycin C and anti-TRAIL antibody were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-PARP, anti-caspase 8/9/3, anti-cleaved caspase 9/3, antiphosphorylated (Thr183/Tyr185) JNK, anti-JNK, anti-BclxL, anti-COX-IV and anti-human influenza hemagglutinin (HA) antibody were purchased from Cell Signaling (Danvers, MA, USA). Anti-phosphorylated Bcl-xL (S62) antibody was purchased from Millipore (Billerica, MA, USA) and anti-cytochrome c antibody and anti-Beclin-1 were from BD Pharmigen (San Jose, CA, USA). Anti-actin antibody and other chemicals were purchased from Sigma (St. Louis, MO, USA).
Shuttle vector construction pFETZ was kindly provided by Dr. Y He (Immunotherapy Center, Medical College of Georgia, GA, USA) [54] . This vector contains cDNA for the extracellular domain of Flt3L, a ligand for Flt3 tyrosine kinase receptor (a.a. 1-81), fused to a leucine zipper domain and the extracellular domain of TRAIL (a.a. 95-281) and expresses a secretable form of TRAIL fusion protein [55] . pAdlox-FETZ was made by inserting the SalI/BamHI fragment from pFETZ into SalI/BamHI-cut pAdlox shuttle vector. The complete shuttle vector was co-transfected into CRE8 cells with w5 viral genomic DNA for homologous recombination as described below.
Adenoviral vector construction
Recombinant adenovirus was constructed by employing the Cre-lox recombination system [56] . The selective cell line CRE8 has a b-actin-based expression cassette driving a Cre recombinase gene with an N-terminal nuclear localization signal stably integrated into 293 cells. Transfections were done by using Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA). Cells were split into T25-flasks 1 day before transfection. For the production of recombinant adenovirus, 2 lg of Adlox/FETZ and 2 lg of w5 viral genomic DNA were co-transfected into CRE8 cells in the presence of caspase inhibitor z-VAD-fmk (20 lM). The recombinant adenoviruses were generated by intramolecular homologous recombination between the shuttle vector and w5 viral DNA. The new virus had an intact packaging site and carried a recombinant gene. Plaques were harvested, analyzed and purified.
Drug treatment
Drug treatments were accomplished by aspirating the medium and replacing it with new medium containing drugs.
Hyperthermia treatment
Cells cultured in 35 mm or 100 mm dishes were sealed with parafilm and were placed a circulating water bath (Heto, Thomas Scientific, Denmark), which was maintained within 0.02°C of the desired temperature.
Survival assay
One or 2 days prior to the experiment, human colorectal carcinoma LS174T cells were plated into six well plates. For trypan blue exclusion assay, trypsinized cells were pelleted and resuspended in 0.2 mL of medium, 0.5 mL of 0.4 % trypan blue solution, and 0.3 mL of phosphate-buffered saline solution (PBS). The samples were mixed thoroughly, incubated at room temperature for 15 min, and examined by automated cell counter (LUNA, Logos Biosystems, Annandale, VA, USA). At least 300 cells were counted for each survival determination.
Protein extracts and polyacrylamide gel electrophoresis (PAGE) Cells were scraped with 1 9 Laemmli lysis buffer [including 2.4 M glycerol, 0.14 M Tris (pH 6.8), 0.21 M SDS, and 0.3 mM bromophenol blue] and boiled for 3 min. Protein concentrations were measured with BCA protein assay reagent (Pierce, Rockford, IL, USA). The samples were diluted with 1 9 lysis buffer containing 20 mM dithiothreitol (DTT), and an equal amount of protein was loaded on 10-15 % SDS-polyacrylamide gels. SDS-PAGE analysis was performed using a Hoefer gel apparatus.
Immunoblot analysis
Proteins were separated by SDS-PAGE, electrophoretically transferred to nitrocellulose membranes and blocked with 5 % skim milk in TBS-Tween 20 (0.05 %, v/v) for 30 min. The membrane was incubated with primary antibodies for 2 h at room temperature or overnight at 4°C. Horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized by the enhanced chemi-luminescence protocol (ECL, Amersham, Arlington Heights, IL, USA).
Annexin V binding
The translocation of phosphatidylserine, one of the markers of apoptosis, from the inner to the outer plasma membrane was detected by binding of allophycocyanin (APC)-conjugated Annexin V. LS174T cells were plated into plates, treated with drugs for 24 h and stained with mouse antihuman Annexin V antibody and propidium iodide (PI). The staining was terminated and cells were immediately analyzed by flow cytometry.
JC-1 mitochondrial membrane potential assay
After drug treatment, cells were stained using JC-1 mitochondrial membrane potential detection kit (Invitrogen) for 10 min and analyzed by flow cytometry. Fluorescence intensity was measured with the Accuri C6 flow cytometer (Accuri Cytometers, Inc., San Jose, CA, USA). Results were analyzed with VenturiOne software (Applied Cytometry, Inc., Plano, TX, USA).
Cytochrome c release assay
To determine the release of cytochrome c from the mitochondria, LS174T cells growing in 100 mm dishes were used. After drug treatment, mitochondria and cytosolic fractions were prepared from treated cells by using a Mitochondrial Fractionation Kit (Active Motif, Carlsbad, CA, USA) following company instructions and reagents included in the kit. Cytosolic fractions were subjected to SDS-PAGE and analyzed by immunoblotting using anticytochrome c antibody. Equal loading of the mitochondrial pellets was confirmed with anti-COX IV antibody.
Bak oligomerization
After drug treatment, cells were collected and resuspended in homogenization buffer. The cell suspension was homogenized several times and centrifuged at 1,0009g for 10 min at 4°C to obtain nuclear pellets. Supernatant was transferred to a new 1.5 mL tube and spun at 10,0009g for 15 min at 4°C to pellet the mitochondria. Isolated mitochondrial fractions and cytosolic fractions were crosslinked with 1 mmol/L dithiobis (Pierce) for 1 h at room temperature. After cross-linking, the mitochondria were pelleted and samples were subjected to SDS-PAGE under nondenaturing conditions followed by immunoblotting for Bak.
Stable transfection
Cells stably overexpressing HA-Bcl-xL wild-type (WT) or mutant types were prepared by transfecting CX-1 cells with human Bcl-xL tagged with HA epitope in pCDNA3.1 vector: HA-Bcl-xL WT, HA-Bcl-xL S62A (mutation of serine 62 to alanine), and HA-Bcl-xL S62D (mutation of serine 62 to aspartate; a kind gift from Dr. TC Chambers, University of Arkansas). Cells were maintained in 500 lg/ mL G418.
Immunoprecipitation
Briefly, cells were pelleted and lysed by CHAPS buffer with protease inhibitor cocktail. Cell lysates were completely disrupted by repeated aspiration through a 27 gauge needle. Cell debris was removed and protein concentration was determined by BCA Protein Assay Reagent. For immunoprecipitation, 500 lg of lysate was incubated with 1 lg of rabbit anti-Bcl-xL/anti-HA antibody or rabbit IgG at 4°C overnight, followed by the addition of protein G-agarose beads and rotation at 4°C for 4 h. Immunoprecipitates were collected by centrifugation and the pellet was dissolved in electrophoresis sample buffer for heat denaturation. The immune complexes were subjected to SDS-PAGE followed by immunoblot analysis.
Statistical analysis
Statistical analysis was carried out using GraphPad InStat 3 software (GraphPad Software, Inc., San Diego, CA, USA).
Significance was set at values of *(p \ 0.05), **(p \ 0.01), or ***(p \ 0.001).
Results
Characterization of a secretory TRAIL-armed adenoviral vector
We constructed pAdlox-FETZ shuttle vector which has a CMV promoter-driven secretory human Flt3 ligand-isoleucine zipper-human TRAIL fusion protein gene. This plasmid encoded the secretable form of chimeric TRAIL proteins which were detected in Fig. 1a . Next, we constructed a secretory TRAIL-armed adenoviral vector (Ad.TRAIL) and characterized the vector. Data from Fig. 1b shows an expression of TRAIL in Ad.TRAIL infected 293 cells in the absence/presence of caspase inhibitor z-VAD-fmk, which was added to prevent TRAILinduced apoptosis. Unlike most cancer cell lines, immortalized normal human embryonic kidney 293 cells were resistant to TRAIL. To examine an apoptotic capacity of Ad.TRAIL, human colon adenocarcinoma LS174T cells were infected with various multiplicity of infection (MOI) of Ad.TRAIL and its control adenoviral construct encoding green fluorescent protein (Ad.GFP). As shown in Fig. 1c , Ad.TRAIL induced PARP cleavage, the hallmark feature of apoptosis. TRAIL-induced PARP cleavage was dependent upon MOI. Unlike Ad.TRAIL, Ad.GFP induced minimal apoptosis only at MOI of 100. Next, we investigated the kinetics of apoptosis after Ad.TRAIL infection in human colorectal carcinoma HCT116 and LS174T cells. Figure 1d shows that PARP cleavage occurred 24 h after infection in both cell lines.
Synergistic induction of apoptosis by Ad.TRAIL in combination with mitomycin C and hyperthermia
To investigate the effect on cell viability of the application of Ad.TRAIL in combination with mitomycin C and hyperthermia, LS174T cells were infected with Ad.TRAIL (MOI 25) and treated with 5 lg/mL mitomycin C for 24 h. After treatment, the cells were heated at 42°C for 1 h and incubated at 37°C for 3 h and then cell viability was determined by trypan blue dye exclusion assay. As shown in Fig. 2a , synergistic cytotoxic effect was observed in Ad.TRAIL ? mitomycin C or Ad.TRAIL ? mitomycin C ? hyperthermia compared with any single treatment (p \ 0.05). We further investigated whether the combinatorial treatment-induced cytotoxicity was associated with Figures 2b, c clearly show that treatment with Ad.TRAIL in combination with mitomycin C and hyperthermia enhanced synergistic induction of apoptotic death. These synergistic effects were due to an increased activation (cleavage) of caspase 8/9/3 and thus, the hallmark feature of apoptosis, PARP cleavage (Fig. 3a) . Similar results were observed in LS180, CX-1 and HCT116 cell lines (Figs. 3b, c, d ). These results indicate that synergistic induction of apoptosis by combinatorial treatment with mitomycin C/Ad.TRAIL/hyperthermia is mediated through an increase in caspase activation.
Role of the JNK-Bcl-xL-Bak pathway in the combinatorial treatment-induced apoptosis
We previously reported that the JNK-Bcl-xL pathway plays an important role in the synergistic effect on apoptosis of treatment with multiple cytotoxic agents [43, 57] . This possibility was examined during treatment with mitomycin C/Ad.TRAIL/hyperthermia. Phosphorylation of JNK and Bcl-xL was observed during treatment with mitomycin C/Ad.TRAIL/hyperthermia in LS174T cells (Fig. 4a) . Even with treatment with only mitomycin C, phosphorylation of JNK and Bcl-xL was detected. Moreover, an increase in phosphorylation was observed during combinatorial therapy. Data from immunoprecipitation assay show that the combinatorial treatment induced the dissociation of Bak from Bcl-xL (Fig. 4b) . We previously reported that phosphorylation of Bcl-xL alters the interactions between Bcl-xL and Bax and then leads to Bax oligomerization [43] . Since the presence of Bax was not (Fig. 4c) . Oligomerized Bak may bind to the mitochondria, altering mitochondrial membrane potential (Fig. 4d) and causing a cytochrome c release (Fig. 4e) .
Alteration of interactions between Bcl-xL and Beclin-1 and cleavage of Beclin-1 during the combinatorial treatment To examine whether phosphorylation of the S62 residue on Bcl-xL is important for apoptosis, CX-1 cells were stably transfected with plasmid containing HA-Bcl-xL WT, phosphor-defective HA-Bcl-xL S62A or phosphor-mimic HA-Bcl-xL S62D. Figure 5a shows that HA-Bcl-xL S62A, but not HA-Bcl-xL WT and HA-Bcl-xL S62D, inhibited apoptosis. These results suggest that the phosphorylation of Bcl-xL plays an important role in the combinatorial treatment-induced apoptosis. We previously reported that phosphorylation of Bcl-xL affects interaction between BclxL and Beclin-1, causing dissociation of Beclin-1 from Bcl-xL [57] . Data from immunoprecipitation assay show that overexpression of dominant-negative mutant type of Bcl-xL S62A, but not wild type Bcl-xL WT or dominantpositive mutant type of Bcl-xL S62D, suppressed the dissociation of Beclin-1 from Bcl-xL (Fig. 5b) . Several researchers reported that Beclin-1 has two cleavage sites at D133 and D146 residues [58] and that Beclin-1 is cleaved by caspase 8, and C-terminal fragment of Beclin-1 localizes at the mitochondria and then induces cytochrome c release [58, 59] . Figure 6a shows that the combinatorial treatment enhanced Beclin-1 cleavage. On Fig. 6b , data from Beclin-1 double mutant (D133A/D146A) knock-in HCT116 cells show suppression of cleavage of PARP and caspase 8/9/3 (apoptosis). Beclin-1, a mammalian homolog of yeast autophagy-related protein 6 (Atg6), functions in autophagy by initiating autophagosome formation [60] . However, it has been suggested that crosstalk between apoptosis and autophagy is associated with caspase-mediated cleavage of Beclin-1 which destroys its pro-autophagic activity and can then amplify mitrochondrion-mediated apoptosis through the cleaved C-terminal fragment [58] . Our data suggest that the combinatorial treatment-induced synergistic apoptotic death is mediated through Beclin-1 cleavage.
Discussion
Several conclusions can be drawn upon consideration of the data presented here. First, a combinatorial treatment of Ad.TRAIL, mitomycin C and hyperthermia synergistically induces apoptosis. Second, the JNK-Bcl-xL-Bak pathway plays an important role in the apoptosis through activating the mitochondria-dependent pathway. Third, a combinatorial treatment of Ad.TRAIL, mitomycin C and hyperthermia induces dissociation of Beclin-1 from Bcl-xL and promotes Beclin-1 cleavage which results in enhancement of apoptosis.
The DNA damage surveillance network may orchestrate cellular responses to mitomycin C-induced DNA damage through the recruitment of DNA damage sensing molecules, transducer and effector proteins [61] . Ataxia telangiectasia mutated (ATM) and Nijmegen breakage syndrome (NBS1) cooperatively sense DNA damage and post-translationally modify transducers such as BRCA1 (early-onset familial breast and ovarian cancer), MDC1 (mediator of DNA damage checkpoint 1), 53BP1 (p53-binding protein 1), and c-Abl [62, 63] . These modified transducer proteins amplify and transduce the signals to downstream effectors such as H2AX, p53, Chk2 and JNK [64] [65] [66] [67] [68] [69] [70] [71] [72] . It is possible that mitomycin C-activated JNK is mediated through the ATM-c-Abl signal transduction pathway. This possibility needs to be further investigated.
We previously reported that Bcl-xL undergoes phosphorylation in response to treatment with oxaliplatin, TRAIL/mapatumumab and hyperthermia [42, 43, 57, [73] [74] [75] . Bcl-xL phosphorylation requires activated JNK, which can recognize a proline residue on the carboxyl side of the phospho-acceptor [76] . Some studies reported Bcl-xL phosphorylation to occur on serine 62, while others reported it to occur on threonines 47 and 115 [77, 78] . This study with site-directed mutagenesis at Ser-62 showed that cells expressing a validated phospho-defective Bcl-xL mutant are resistant to the combinatorial treatment of Ad.TRAIL, mitomycin C and hyperthermia-induced apoptosis, whereas cells expressing a phospho-mimic BclxL are sensitive to the combinatorial treatment-induced apoptosis, indicating that phosphorylation at Ser-62 is a key regulatory mechanism for antagonizing anti-apoptotic function in the combinatorial treatment.
Previous studies have shown that JNK1-mediated phosphorylation of Bcl-2 at residues T69, S70, and S87 is b Fig. 4 Ad.TRAIL in combination with mitomycin C and hyperthermia-induced activation of the JNK-Bcl-xL pathway, Bak oligomerization, mitochondrial membrane potential change and cytochrome c release. LS174T cells were treated with Ad.TRAIL (MOI 25) or/and mitomycin C (5 lg/mL) for 24 h and exposed to normothermia (37°C) or hyperthermia (42°C) for 1 h, and then incubated for 3 h at 37°C. e Cytochrome c release into cytosol was determined by immunoblotting for cytochrome c in the cytosolic fraction. Actin was used to confirm the equal amount of proteins loaded required for dissociation of Bcl-2 from Beclin-1 and autophagy activation [79] . Unlike Bcl-2, data from Fig. 5b suggests that for Bcl-xL, phosphorylation only at residue S62 may be sufficient for Bcl-xL dissociation from Beclin-1. It was reported that D133 and D146 of Beclin-1 are cleaved by caspase 8 during apoptosis [58, 59] . Caspase 8-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria [58, 59] . Studies with the caspase 8-resistant Beclin-1 knockin cell line clearly demonstrate that the combinatorial treatment-induced Beclin-1 cleavage and apoptosis were reduced (Fig. 6b) , and Beclin-1's autophagy-promoting function was restored (data not shown) in Beclin-1 KI HCT116 cells. We reported that hyperthermia has a synergistic effect with TRAIL in causing apoptosis [40] [41] [42] . We also reported that hyperthermia triggers down-regulation of c-FLIP L (long form of cellular FLICE-inhibitory protein), an anti-apoptotic molecule, through ubquitination in several colon cancer cell lines [50] . It has been found that c-FLIP splice variants (long and short form) bind to FADD and/or caspase 8/10 and inhibit their activation [51] [52] [53] . Thus, down-regulation of c-FLIP L is probably responsible for hyperthermia-enhanced TRAIL cytotoxicity. Interestingly, long-term pretreatment with TRAIL by expressing TRAIL from Ad.TRAIL showed a minimal synergistic effect with hyperthermia, even though down-regulation of c-FLIP L was observed (data not shown). This may be due to the activation of TRAIL-associated death signals prior to hyperthermia. This possibility needs to be further studied.
Our data illustrate that a combinatorial treatment of Ad.TRAIL, mitomycin C and mild hyperthermia synergistically induces apoptosis and effectively activates the mitochondria-dependent apoptotic pathway by activating the JNK-Bcl-xL-Bak pathway. Moreover, our data suggest that Beclin-1 is dissociated from phosphorylated Bcl-xL and cleaved during treatment with Ad.TRAIL, mitomycin C and hyperthermia. The cleavage of Beclin-1 promoted the combinatorial treatment-induced apoptotic death. The studies presented here further elucidate a crosstalk between the JNK-Bcl-xL-Bak pathway and the Bcl-xL/Beclin-1-mediated pathway during treatment with Ad.TRAIL, mitomycin C and hyperthermia. A greater understanding of these interactions may be critical for enhancing the combinatorial treatment. 
